CC_586764/2023

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

Verletzungs-Hauptverfahren:UPC_CFI_14/2023

NichtigkeitWiderklage auf NichtigkeitMunich CDCounter claim for revocationCase Closed

2024-07-16Nichtig erklärtrevocation_meritsCounterclaim for revocation
The patent EP 3 666 797 B1 was revoked in its entirety for all Contracting Member States in which revocation was requested. The Main Request and all 17 Auxiliary Requests were found to lack inventive step. The defendant (patent proprietor Amgen) was ordered to bear the claimant's legal costs, agreed at EUR 1.375 million.